In this issue: 2G uest editorial The CLTI conundrum: My spirited journey through the CLTI saga
11 T raining APDVS launches vascular surgery curriculum e-book for medical students
9M embership SVS announces merger that creates the new Section on Ambulatory Vascular Care
SEPTEMBER 2024 Volume 20 Number 9
THE OFFICIAL NEWSPAPER OF THE
12 Executive Board SVS president champions continuity and unified future
www.vascularspecialistonline.com
STUDY SHEDS LIGHT ON VASCULAR-SPECIFIC ADVANCED PRACTICE PROVIDER EXPERIENCE
EASTERN VASCULAR
‘Select CLTI patients may be safely treated in the office-based lab’ Single-center analysis finds outpatient setting met SVS objective performance goals By Bryan Kay
By Jocelyn Hudson
Vascular Surgery (SVS) objective performance goals for revascularization carried out for CLTI of 55% freedom from reintervention, 84% limb salvage and 80% survival at one year. The data, from September 2016–February 2023, are to be presented at the 2024 annual meeting of the Eastern Vascular Society (EVS) in Charleston, South Carolina (Sept. 19–22), by Moira McGevna, a medical student at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey, who worked on the project during a research year at NYU under
IN A RECENTLY CONDUCTED survey, over 200 U.S. advanced practice providers (APPs) in vascular surgery cited performing at the top of their license as the most important determinant of job satisfaction. This and other key findings are set to be presented at the Midwestern Vascular Surgical Society (MVSS) annual meeting (Sept. 12–14) in Chicago. The research—conducted by author Saideep Bose, MD, and colleagues—investigated scope of practice, workplace satisfaction and burnout among vascular-specific APPs who practice in the U.S. Bose, a vascular surgeon and assistant professor at Saint Louis University in Missouri, told Vascular Specialist ahead of his MVSS presentation that there is a “strong contingent” of APPs in vascular practice. “The main issue is that we don’t know how people in these APP positions feel about their careers or their jobs and if they feel like they are being utilized effectively or just being asked to do tasks that no one else wants to do,” he said, highlighting the genesis for the research. In order to illuminate the experience of vascularspecific APPs, the researchers conducted a survey of 50 questions. The main component was the Mini Z survey—a
See page 4
See page 6
OBL
A
retrospective analysis of endovascular interventions performed for chronic limb-threatening ischemia (CLTI) in an office-based lab (OBL) associated with a large New York City medical center across seven years determined that carefully selected patients may be treated safely in the outpatient setting. Researchers from NYU Langone Medical Center report that 44.8% of the 230 patients included in the study required ipsilateral reintervention, with 30.4% warranting inpatient reintervention; and 20.4% required ipsilateral amputation, with 9.1% undergoing major amputation. All-cause mortality was 16.5% at three-year follow-up. This is set against Society for
POWER AND PRECISION: PRECISION: Risk Info: angiodynamics.com/about-us/risk-information. Auryon and the Auryon logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or a subsidiary. © 2024 AngioDynamics, Inc. US/PA/AD/2861 Rev 01 08/2024
Vascular Specialist 9400 W. Higgins Road, Suite 315 Rosemont, IL 60018
IM
PAID
CHANGE SERVICE REQUESTED
PRESORTED STANDARD MAIL U.S. POSTAGE